Anika Therapeutics, Inc. Forecast, price target & analysts
Anika Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Anika Therapeutics, Inc. Classifications & Recommendation
Anika Therapeutics, Inc. Price Target
| Target Price | $21.42 |
| Price | $20.70 |
| Potential |
3.48%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Anika Therapeutics, Inc. 2027 .
The average Anika Therapeutics, Inc. target price is $21.42.
This is
3.48%
register free of charge
$22.05
6.52%
register free of charge
$21.21
2.46%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Anika Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Anika Therapeutics, Inc. stock has an average upside potential 2027 of
3.48%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 112.82 | 124.68 |
| 5.91% | 10.51% | |
| EBITDA Margin | -4.72% | 15.41% |
| 197.32% | 426.80% | |
| Net Margin | -9.64% | -0.11% |
| 79.49% | 98.86% |
4 Analysts have issued a sales forecast Anika Therapeutics, Inc. 2026 . The average Anika Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Anika Therapeutics, Inc. EBITDA forecast 2026. The average Anika Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Anika Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Anika Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.75 | -0.01 |
| 80.42% | 98.67% | |
| P/E | negative | |
| EV/Sales | 1.93 |
4 Analysts have issued a Anika Therapeutics, Inc. forecast for earnings per share. The average Anika Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Anika Therapeutics, Inc....
Current Anika Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Feb 27 2026 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Jan 09 2026 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Sep 23 2025 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Jul 31 2025 |
| Barrington Research |
Locked
➜
Locked
|
Locked | May 12 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Feb 27 2026 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Jan 09 2026 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Nov 06 2025 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Sep 23 2025 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Jul 31 2025 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
May 12 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
